Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Transgene (Paris:TNG) (Euronext Paris: FR0005175080) today issues its quarterly financial report as of March 31, 2013 (first quarter of 2013).
During the first quarter of 2013, revenue from collaborative and licensing agreements were principally composed of: (i) manufacturing services for Jennerex, Inc., strategic partner of Transgene for the development of JX594/TG6006, (ii) revenue from the payment made in 2010 by Novartis for the exclusive option agreement on TG4010, and (iii) royalty from technologies or products licensed by Transgene.
Help employers find you! Check out all the jobs and post your resume.
Transgene (Paris:TNG) (Euronext Paris: FR0005175080) today issues its quarterly financial report as of March 31, 2013 (first quarter of 2013).
During the first quarter of 2013, revenue from collaborative and licensing agreements were principally composed of: (i) manufacturing services for Jennerex, Inc., strategic partner of Transgene for the development of JX594/TG6006, (ii) revenue from the payment made in 2010 by Novartis for the exclusive option agreement on TG4010, and (iii) royalty from technologies or products licensed by Transgene.
Help employers find you! Check out all the jobs and post your resume.
